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Influence of gender of
physicians and patients on
guideline-recommended
treatment of chronic heart
failure in a cross-sectional
study
We read with interest the study by Baumhäkel
et al.1 regarding the influence of gender of phys-
icians and gender of patients on treatment
decisions in the care of congestive heart
failure. This study takes the issue of gender dis-
parities in clinical settings an important step
forward, indicating that not only physician’s
behaviour, such as time spent per patient, is
different, as shown previously,2 but also that a
gender effect may actually translate into differ-
ences in medical treatment.
In this study, the authors conclude that
female patients are receiving inferior
therapy, especially when treated by a male
cardiologist. We believe that such a strong
conclusion cannot decisively be made from
the data presented. In observational studies
such as the one presented here, it is difficult
to distinguish between a direct relationship
and a statistical association mediated by
confounding factors. No doubt, controlled
trials would not apply, randomization would
be difficult to perform, and blinding even
impossible. However, alternative analytical
approaches for observational studies such as
propensity score or instrumental variable-
based analyses3 could further reduce
potential confounding and may have shown
different results.
The authors show that fewer female
patients were receiving beta-blockers com-
pared with men. However, such a difference
was present independent of the gender of
the treating physician. Why is that? Aetiolo-
gies for HF and co-morbidities differ signifi-
cantly between male and female patients.
Coronary artery disease (CAD) prevalence
was significantly higher in men, whereas dias-
tolic heart failure may have been more preva-
lent in women. This ‘double indication’ of
CAD and HF likely explains, at least in part,
the higher rate of beta-blocker treatment in
male patients.
The authors also observed that patients
treated by male physicians received beta-
blockers less frequently. However, the pro-
portion of patients with CAD treated by male
physicians was somewhat lower in general,
which may explain part of that phenomenon.
Most critically, this study makes no asser-
tions regarding clinical outcomes of patients
as stratified by gender. In fact, as the
authors mention, several studies have shown
that female patients with congestive heart
failure actually have more favourable out-
comes than male patients.4,5 Given this
reality, it becomes difficult to assert, as the
authors do, that female patients are receiving
inferior treatment—if that were the case,
would their survival really be superior?
Certainly, there is room for confounding in
this study with regard to the influence of
patient or physician gender on treatment, and
with regard to a gender interaction effect.
Given all of these issues, we consider the state-
ment by the authors that ‘A female patient was
likely to receive the worst medical treatment
from a male physician . . . ’ to be inflammatory
and unsupported by the evidence presented in
this manuscript.
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Influence of gender of
physicians and patients on
guideline-recommended
treatment of chronic heart
failure in a cross-sectional
study: reply
We thank Drs Duvernoy and Meier for their
comments on our study.1 Evaluation of the
influence of physicians’ gender on quality of
medical treatment is difficult to perform.
You are right with the suggestion that con-
trolled trials cannot be applied to this ques-
tion. Thus, we chose an observational
survey with all of its disadvantages.
However, we tried to consider the possible
confounders in the multivariate analysis.
Nevertheless, we think that there might be
an influence of physicians’ gender on
medical treatment of chronic heart failure in
the population evaluated. Furthermore,
there could be country-specific differences
in health care systems or even education of
physicians. Therefore, we suggest that similar
studies should be performed in different
countries and health care systems, because
our results will not necessarily be valid in
other countries.
Prescription of beta-blockers might be
biased by higher prevalence of coronary
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